Scientists bet on 'effective' antibodies
A team of Chinese scientists has isolated several antibodies that it says are “extremely effective” at blocking the ability of the novel coronavirus to enter cells, which eventually could be helpful in treating or preventing COVID-19.
There is currently no proven effective treatment for the disease, which is spreading across the world in a pandemic that has infected more than 850,000 and killed 42,000.
Zhang Linqi at Tsinghua University in Beijing said a drug made with antibodies like the ones his team have found could be used more effectively than the current approaches, including what he called “borderline” treatment such as plasma.
Plasma contains antibodies but is restricted by blood type.
In early January, Zhang’s team and a group at the third People’s Hospital in Shenzhen began analyzing antibodies from blood taken from recovered COVID-19 patients, isolating 206 monoclonal antibodies which showed what he described as a “strong” ability to bind with the virus’ proteins.
They then conducted another test to see if they could actually prevent the virus from entering cells, he said.
Among the first 20 or so antibodies tested, four were able to block viral entry and of those, two were “exceedingly good” at doing so, Zhang said.
The team is now focused on identifying the most powerful antibodies and possibly combining them to mitigate the risk of the new coronavirus mutating.
If all goes well, interested developers could mass produce them for testing, first on animals and eventually on humans.
The group has partnered with a Sino-US biotech firm, Brii Biosciences, in an effort “to advance multiple candidates for prophylactic and therapeutic intervention,” according to a statement by Brii.
“The importance of antibodies has been proven in the world of medicine for decades now,” Zhang said. “They can be used to treat cancer, autoimmune diseases and infectious diseases.”
The antibodies are not a vaccine but could potentially be given to at-risk people with the aim of preventing them from contracting COVID-19.
Normally it takes around two years for a drug even to get close to approval for use on patients, but the COVID-19 pandemic means things are moving faster, Zhang said. He hopes the antibodies can be tested on humans in six months.